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Blood genomic profiling has been applied to disorders of the blood and various organ systems including brain to elucidate disease mechanisms
and identify surrogate disease markers. Since most studies have not examined specific cell types, we performed a preliminary genomic survey of
major blood cell types from normal individuals using microarrays. CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ natural killer cells, and
CD14+ monocytes were negatively selected using the RosetteSep antibody cocktail, while polymorphonuclear leukocytes were separated with
density gradient media. Genes differentially expressed by each cell type were identified. To demonstrate the potential use of such cell subtype-
specific genomic expression data, a number of the major genes previously reported to be regulated in ischemic stroke, migraine, and Tourette
syndrome are shown to be associated with distinct cell populations in blood. These specific gene expression, cell-type-related profiles will need to
be confirmed in larger data sets and could be used to study these and many other neurological diseases.
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microarrays has been applied to malignant and immune
disorders, including leukemia, lymphoma, systemic lupus
erythematosis, rheumatoid arthritis, and many others [1–4].
This approach has helped identify important diagnostic and
prognostic markers as well as potential therapeutic targets.
This approach has also been extended to many diseases of
other organ systems. It is likely that many inflammatory,
autoimmune, and genetic factors could affect gene expression
of peripheral blood cells without causing overt changes to
hematological and immunological phenotypes. Proof-of-prin-⁎ Corresponding author. MIND Institute, University of California at Davis,
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doi:10.1016/j.ygeno.2006.02.003ciple blood genomic studies have been performed in animals
[5] and humans [6,7]. Subsequent studies have demonstrated
characteristic blood genomic patterns for acute ischemic stroke
[8], migraine headache [9], Tourette syndrome [10], renal cell
carcinoma [11], multiple sclerosis [12], benzene exposure
[13], trauma [14], and neurogenetic disorders including
neurofibromatosis type I, tuberous sclerosis type II, Down
syndrome [7,15], and Huntington chorea [16]. The study of
blood gene expression profiles appears to be a promising
approach that may provide mechanistic insights and surrogate
markers for many diseases.
Several blood RNA isolation methods have been used to
date. These include methods starting with whole blood,
mononuclear cells, and buffy coat [6,7,11,14,17,18]. How-
ever, the RNA isolated using these methods comes from
various blood cell subsets that originate from different
Table 1
Results of the qualitative analysis
Cell type Number of
present probe
sets
Percentage of
present probe
sets
Number of
unique probe
sets
Percentage of
unique probe
sets
PMN 13,139 24.0% 155 1.2%
CD14+ monocyte
or platelet
17,426 31.9% 152 0.9%
CD19+ B cell 20,009 36.6% 120 0.6%
CD4+ T cell 19,909 36.4% 24 0.1%
CD8+ T cell 19,321 35.3% 8 0.0%
CD56+ NK cell 19,777 36.2% 42 0.2%
A total of 54,675 probe sets that examined approximately 39,500 genes were
surveyed on each array. “Present” probe sets include probe sets that have 3
present detection calls for a specific cell type regardless of the calls for other cell
types. “Unique” probe sets include probe sets that have 3 present calls for a cell
type and 15 absent calls for every other cell type.
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logical functions, and, most likely, have very different geno-
mic expression signatures. It has been recognized that age
and gender and the different composition of blood cells from
each individual represent a major source of normal variation
of blood gene expression [6,7]. In addition, a disease may
predominantly affect one specific blood cell subtype while
sparing others. Therefore, characterizing the contribution of
every blood cell subtype to the overall blood genomic pattern
may be essential to distinguish significant genomic changes
from noise, interpret the disease-related patterns, and decide on
the proper blood cell types to perform follow-up confirmatory
analyses.
Expression profiles of blood cells such as T lymphocytes
[14,19] and platelets [18,20] have been described. However,
studies that compare directly the whole genomic expression
profiles of several major blood cell subtypes have not been
performed in detail. In this study, we attempted to build a
preliminary gene expression database by comparing major
leukocyte subsets from three healthy donors, including
polymorphonuclear cells (PMN), monocytes, B cells, CD4+ T
cells, CD8+ cytotoxic T cells, and natural killer (NK) cells to
determine whether there is likely to be a unique expression
signature of each cell type. To demonstrate the utility of these
expression signatures, we applied these data to the whole blood
genomic profiles of several neurological diseases that we have
studied previously, including acute ischemic stroke [8],
migraine [9], and Tourette syndrome [10], to demonstrate that
the blood genomic signatures of each of these conditions can be
ascribed to certain blood cell subtypes being affected by each
disease. Future studies likely could determine not only whether
hematological and systemic diseases affect gene expression in
specific subsets of blood cells, but also whether the diseases
affect specific signaling pathways in specific subsets of cells in
blood.
Results
Qualitative analysis
The numbers of “present” and “unique” genes for each cell
type are listed in Table 1. Of the 54,675 genes, higher
percentages of the genes are expressed (present) by lympho-
cytes, including B (36.6%), CD4 (36.4%), CD8 (35.3%), and
NK cells (36.2%), than by monocytes/platelets (31.9%) and
PMNs (24.0%). However, there are higher percentages of
unique genes for PMNs (1.2%) and monocytes/platelets (0.9%)
than for lymphocytes (0–0.6%) (Table 1). Among the
lymphocytes, B cells have the highest number of characteristic
genes, while unique transcripts for T cells are relatively scarce
due to the largely similar profiles for T cell subsets CD4+ and
CD8+ and the profiles for NK cells.
Quantitative analysis
Among 54,675 genes (probe sets) on the array, a total of
2635 are differentially expressed between the blood cell types(parametric analysis of variance (ANOVA), p < 0.05 with
Bonferroni correction), among which 269 are significant
using a Student–Newman–Keuls post hoc test. For practical
reasons, we focused on the 269-probe set list since it should
contain the most characteristic genes and potentially contain
genomic expression markers for each cell lineage. These 269
genes/probe sets were mathematically separated into nine
clusters of relatively unique expression profiles using a
hierarchical algorithm [25] as demonstrated in Fig. 1. The
pattern of expression of each gene in each cluster and the fold
changes of the genes are shown in separate panels on the
right side of Fig. 1. In general the fold changes varied as
much as 10- to 100-fold. The genes in each cluster are listed
in Table 2. The left side of Fig. 1 not only shows the gene
expression (y axis) for different blood cell types (x axis), but
also shows the gene expression of the three individuals
performed for each cell type. Note that the expression levels
(red—fivefold increase; bright green—fivefold decrease) for
each individual are extremely reproducible between cell types
and between genes. This indicates that the microarray
technological variables have a minimal effect upon the
expression profiles shown in Fig. 1 and indicate that our
criteria for selecting genes for each cell type are stringent and
not significantly affected by individual differences at least in
this preliminary study.
Cellular origin of blood genes regulated by neurological
diseases
Fig. 2 represents a melding of the data from the current
study with that from our previous disease-specific studies. The
genes that were most highly regulated in ischemic stroke [8],
Tourette syndrome [10], and migraine [9] were selected and
the cell-specific expression of each of those genes (from the
present study) is shown. As demonstrated in Fig. 2, the major
genes up-regulated in whole blood after stroke were expressed
mainly by PMNs and monocytes/platelets. The major genes
up-regulated by Tourette syndrome were mostly from NK cells
and/or CD8+ T cells. The major genes up-regulated by
migraine were predominantly from platelets/monocytes,
Fig. 1. A total of 269 genes that are differentially expressed between blood cell types (parametric one-way ANOVA followed by Student–Newman–Keuls post hoc
test, p < 0.05, with Bonferroni multiple comparison correction) were subjected to a hierarchical cluster algorithm with Pearson correlation as a measure of similarity.
(Left) Clusters of genes (nine clusters) with similar expression patterns are displayed from top to bottom (y axis), while cell types are displayed from left to right along
the x axis. For each cell type the results of the three different individuals are shown adjacent to one another. The relative expression of each gene is color coded; red
shows a fivefold increase and green shows a fivefold decrease. (Right, 1–9) Line graphs of genes segregated in the cluster analysis are shown for each of the nine
clusters identified on the left. The x axis shows the cell types and the y axis shows the relative expression values (log scale) as mean −1 standard deviation (log ratio).
695X. Du et al. / Genomics 87 (2006) 693–703though there were some regulated genes from PMNs, CD4+,
CD8+, and NK cells.
Discussion
This study surveyed the global expression profiles of six
major subtypes of blood cells. These data support previous
studies showing that T cells and even platelets have genes that
are expressed in common, but also have genes that are fairly
specific for each cell type and, perhaps more importantly, have
different families of genes that tend to be expressed in a specific
cell type compared to another cell type [14,18–20]. Character-
ization of these profiles should help elucidate the molecular and
genomic basis of the development, differentiation, and function
for each cell type.
Genes in cluster 1 are highly enriched in a monocyte/platelet
population compared to other cell types. The recent literature
shows that many genes from this cluster, such as CLU, GP1BB,
PF4V1, and others (Table 2), are specifically expressed by
platelets [18,20]. Cluster 2 represents genes enriched in PMNs
and monocytes, while genes in cluster 3 are expressed
exclusively by PMNs. Many genes in these two clusters play
crucial roles in innate immunity. These include receptormolecules such as TREM1 [26], FPRL1 [27], and TLR2 [28],
which are involved in microbial recognition and lead to
phagocyte activation and the amplification of the inflammatory
response. There are effector molecules such as MMP9 [29];
S100 proteins P, A9, and A12 [30]; and neutrophil cytosolic
factors 1, 2, and 4, which participate in the neutralization of and
aid clearance of microorganisms and foreign materials, and
scavenger molecules such as IL1R2 [31] and TNFRSF10 [32]
that help suppress excessive and harmful innate immune
responses. In comparison, genes down-regulated in PMNs
(cluster 5) did not provide many functional insights. The low
expression of several ribosomal proteins and transcription
elongation factor in this cluster may indicate a slower rate of
protein translation in PMNs and is consistent with somewhat
fewer RNA transcripts in this cell type (Table 1).
Several molecules expressed by B cells (cluster 4) serve
important central roles in B cell development, proliferation, and
differentiation, such as MS4A1 [33], BLNK [34], and BANK1
[35]. Other molecules, including immunoglobulins and HLA
antigens, important for normal B cell functions, were also
expressed (Table 2). While there are a few common genes
between NK cells and T cells, most notably T cell receptor
subunits and lymphocyte-specific tyrosine kinase (LCK)
Table 2
Results of the quantitative analysis
Common GenBank Description
Cluster 1 a1/3GTP AI972498 Clone IMAGE:4812754,
mRNA
ACRBP AB051833 Acrosin-binding protein
ARHGAP6 NM_001174 Rho GTPase-activating
protein 6
C21orf7 NM_020152 Chromosome 21 open
reading frame 7
CA2 M36532 Carbonic anhydrase II
CD163 NM_004244 CD163 antigen
CD36 NM_000072 CD36 antigen
(collagen type I receptor,
thrombospondin receptor)
CD9 NM_001769 CD9 antigen (p24)
CLEC2 NM_016509 C-type lectin-like
receptor-2
CLU M25915 Clusterin
CSPG2 BF590263 Chondroitin sulfate
proteoglycan 2 (versican)
CXCL5 AK026546 Chemokine (C-X-C motif)
ligand 5
CYP1B1 NM_000104 Cytochrome P450,
family 1, subfamily B,
polypeptide 1
ELOVL7 AW138767 Hypothetical protein
FLJ23563
EMS1 NM_005231 EMS1 sequence
(mammary tumor and
squamous cell
carcinoma-associated
(p80/85 Src substrate)
F13A1 NM_000129 Coagulation factor XIII,
A1 polypeptide
FSTL1 BC000055 Follistatin-like 1
GNG11 NM_004126 Guanine nucleotide
binding protein
(G protein), γ11
GP1BB NM_000407 Glycoprotein Ib
(platelet), β polypeptide
HIST1H3H NM_003536 Histone 1, H3h
ITGB3 M35999 Integrin, β3
(platelet glycoprotein IIIa,
antigen CD61)
KIAA0626 NM_021647
MS4A6A NM_022349 Membrane-spanning
4-domains, subfamily A,
member 6A
MYLK AA526844 MSTP083 mRNA,
complete cds
PF4 NM_002619 Platelet factor 4
(chemokine (C-X-C motif)
ligand 4)
PF4V1 NM_002620 Platelet factor 4 variant 1
PPBP R64130 Proplatelet basic protein
(chemokine (C-X-C motif)
ligand 7)
PRKAR2B NM_002736 Protein kinase,
cAMP-dependent,
regulatory, type II, β
PROS1 NM_000313 Protein S (α)
PTGS1 S36219 Prostaglandin–endoperoxide
synthase 1 (prostaglandin
G/H synthase and
cyclooxygenase)
RIN2 AL136924 Ras and Rab interactor 2
Table 2 (continued)
Common GenBank Description
Cluster 1 SDPR NM_004657 Serum deprivation response
(phosphatidylserine
binding protein)
SDPR BF982174 Serum deprivation response
(phosphatidylserine
binding protein)
SPARC NM_003118 Secreted protein, acidic,
cysteine-rich (osteonectin)
THBS1 BF055462 Thrombospondin 1
TREML1 AF534823 Triggering receptor
expressed on myeloid
cells-like 1
TUBB1 NM_030773 Tubulin, β1
Cluster 2 ANXA3 M63310 Annexin A3
APOBEC3A U03891 Apolipoprotein B mRNA
editing enzyme, catalytic
polypeptide-like 3A
AQP9 NM_020980 Aquaporin 9
BASP1 NM_006317 Brain abundant,
membrane attached
signal protein 1
CD14 NM_000591 CD14 antigen
CLECSF12 AF400600 C-type (calcium-dependent,
carbohydrate-recognition
domain) lectin,
superfamily member 12
CLECSF9 BC000715 C-type (calcium-dependent,
carbohydrate-recognition
domain) lectin,
superfamily member 9
CREB5 AI689210 cAMP-responsive
element binding protein 5
CSF3R NM_000760 Colony-stimulating
factor 3 receptor
(granulocyte)
DKFZP434B044 AL136861 Hypothetical
protein DKFZp434B044
DKFZp434H2111 AK026776 Hypothetical
protein DKFZp434H2111
FCGR2A NM_021642 Fc fragment of IgG,
low affinity IIa, receptor
for (CD32)
FLJ20273 NM_019027 RNA-binding protein
FLJ23091 AL534095 Putative NF-κB
activating protein 373
FLJ23091 AA775681 Putative NF-κB
activating protein 373
FLJ23153 AA650281 Likely ortholog of
mouse tumor
necrosis-α-induced
adipose-related protein
FOS BC004490 v-Fos FBJ murine
osteosarcoma viral
oncogene homolog
FPR1 NM_002029 Formyl peptide
receptor 1
GALNAC4S-6ST NM_014863
GPR86 NM_023914 G-protein-coupled
receptor 86
HIST2H2BE NM_003528 Histone 2, H2be
HSPC159 AK025603 HSPC159 protein
IL13RA1 NM_001560 Interleukin 13 receptor, α1
IL1RN U65590
MNDA NM_002432 Myeloid cell nuclear
differentiation antigen
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Table 2 (continued)
Common GenBank Description
Cluster 2 NCF1 NM_000265 Neutrophil cytosolic
factor 1 (47 kDa,
chronic granulomatous
disease, autosomal 1)
NCF2 BC001606 Neutrophil cytosolic
factor 2 (65 kDa,
chronic granulomatous
disease, autosomal 2)
NCF4 NM_013416 Neutrophil cytosolic
factor 4, 40 kDa
NFE2 L13974 Nuclear factor (erythroid-
derived 2), 45 kDa
PADI4 NM_012387 Peptidyl arginine
deiminase, type IV
QPCT NM_012413 Glutaminyl-peptide
cyclotransferase
(glutaminyl cyclase)
RGS18 AF076642 Regulator of G-protein
signaling 18
S100A12 NM_005621 S100 calcium-binding
protein A12 (calgranulin C)
S100A9 NM_002965 S100 calcium-binding
protein A9 (calgranulin B)
SGK NM_005627 Serum/glucocorticoid
regulated kinase
SLC22A4 NM_003059 Solute carrier family 22
(organic cation transporter),
member 4
SNCA BG260394 Synuclein, α
(non-A4 component
of amyloid precursor)
TLR2 NM_003264 Toll-like receptor 2
TLR4 U93091
TLR8 AW872374
TM6SF1 NM_023003 Transmembrane 6
superfamily member 1
TMG4 BF905445 Transmembrane
γ-carboxyglutamic acid
protein 4
TREM1 NM_018643 Triggering receptor
expressed on myeloid
cells 1
Cluster 3 ABCA1 NM_005502 ATP-binding cassette,
subfamily A (ABC1),
member 1
ACSL1 NM_001995 Acyl-CoA synthetase long-
chain family member 1
ADM NM_001124 Adrenomedullin
C4BPA NM_000715 Complement component 4
binding protein, α
CCR3 NM_001837 Chemokine (C-C motif)
receptor 3
CHI3L1 M80927 Chitinase 3-like 1
(cartilage glycoprotein-39)
CKLFSF2 AA778552 Chemokine-like factor
superfamily 2
CYP4F3 NM_000896 Cytochrome P450,
family 4, subfamily F,
polypeptide 3
EMR3 AF239764 EGF-like module-
containing, mucin-like,
hormone receptor-like 3
G0S2 NM_015714 Putative lymphocyte
G0/G1 switch gene
(continued on next page)
Table 2 (continued)
Common GenBank Description
Cluster 3 GPR109B NM_006018 Putative chemokine receptor
HAL NM_002108 Histidine ammonia-lyase
IL1R2 U64094 Human soluble type II
interleukin-1 receptor
mRNA, complete cds
IL8 NM_000584 Interleukin 8
IL8RB NM_001557 Interleukin 8 receptor, β
KCNJ15 D87291 Potassium inwardly
rectifying channel,
subfamily J, member 15
KCNJ2 BF111326 Potassium inwardly
rectifying channel,
subfamily J, member 2
KRT23 NM_015515 Keratin 23 (histone
deacetylase inducible)
MANSC1 NM_018050 Hypothetical protein
FLJ10298
MGAM NM_004668 Maltase–glucoamylase
(α-glucosidase)
MME AI433463 Membrane
metalloendopeptidase
(neutral endopeptidase,
enkephalinase,
CALLA, CD10)
MMP9 NM_004994 Matrix metalloproteinase 9
(gelatinase B, 92-kDa
gelatinase, 92-kDa type IV
collagenase)
MSCP BG251467 Mitochondrial solute
carrier protein
PBEF1 BC020691 Pre-B-cell colony
enhancing factor 1
PROK2 AF182069 Prokineticin 2
PTGS2 NM_000963 Prostaglandin–endoperoxide
synthase 2 (prostaglandin
G/H synthase and
cyclooxygenase)
S100P NM_005980 S100 calcium-binding
protein P
SEC14L1 AI017770 SEC14-like 1
(Saccharomyces cerevisiae)
TNFAIP6 NM_007115 Tumor necrosis factor,
α-induced protein 6
TNFRSF10C AF012536 Tumor necrosis factor
receptor superfamily,
member 10c, decoy
without an intracellular
domain
VNN3 NM_018399 Vanin 3
Cluster 4 AKAP2 BG540494 Paralemmin 2
ANXA2 NM_004039 Annexin A2
ATP1B3 U51478 ATPase, Na+/K+
transporting,
β3 polypeptide
BANK1 NM_017935 B-cell scaffold protein
with ankyrin repeats 1
BLNK NM_013314 B-cell linker
CCDC6 AK024913 cDNA: FLJ21260 fis,
clone COL01441
CPVL NM_031311 Carboxypeptidase,
vitellogenic-like
CXXC5 BC006428 CXXC finger 5
DPYSL2 NM_001386 Dihydropyrimidinase-like 2
FCRH3 BF514552 Fc receptor-like protein 3
(continued on next page)
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Table 2 (continued)
Common GenBank Description
Cluster 4 FLJ20668 AI707896 Hypothetical protein
FLJ20668
HLA-DPA1 M27487 Major histocompatibility
complex, class II, DP α1
HLA-DPB1 NM_002121 Major histocompatibility
complex, class II, DP β1
HLA-DRB3 AJ297586 Major histocompatibility
complex, class II, DR β3
ICSBP1 AI073984 Interferon consensus
sequence binding protein 1
IGLJ3 X57812 Immunoglobulin λ joining 3
KYNU D55639 Kynureninase
(L-kynurenine hydrolase)
LIPA NM_000235 Lipase A, lysosomal acid,
cholesterol esterase
(Wolman disease)
MGC27165 S55735 Hypothetical protein
MGC27165
MS4A1 BC002807 Membrane-spanning
4-domains, subfamily A,
member 1
MS4A7 AI301935 Membrane-spanning
4-domains, subfamily A,
member 7
NAP1L AI763426 Napsin B pseudogene
P2RX5 U49396 Purinergic receptor P2X,
ligand-gated ion channel, 5
POU2AF1 NM_006235 POU domain, class 2,
associating factor 1
PRDX4 NM_006406 Peroxiredoxin 4
SPAP1 AL833361 SH2 domain-containing
phosphatase anchor protein 1
TCF4 BF592782 Transcription factor 4
TPD52 AA524023 Tumor protein D52
TRAF5 NM_004619 TNF receptor-associated
factor 5
TXNDC5 NM_030810 Thioredoxin domain-
containing 5
VAMP8 NM_003761 Vesicle-associated membrane
protein 5 (myobrevin)
Cluster 5 C1QBP L04636 Complement component 1,
q subcomponent binding
protein
CLNS1A AF005422 Chloride channel,
nucleotide-sensitive, 1A
DOCK10 NM_017718
FLJ11171 AK023183 Hypothetical protein
FLJ11171
FLJ20160 AA133311 FLJ20160 protein
FLJ38426 BF679966 Hypothetical protein
FLJ38426
LRPPRC AI653608 Leucine-rich
PPR-motif-containing
MGC5395 BG287862 Hypothetical protein
MGC5395
MRPL3 BC003375 Mitochondrial ribosomal
protein L3
MRPL9 BC004517 Mitochondrial ribosomal
protein L9
MRPS23 BC000242 Mitochondrial ribosomal
protein S23
NDUFB2 NM_004546 NADH dehydrogenase
(ubiquinone) 1β
subcomplex, 2, 8 kDa
PLAC8 NM_016619 Placenta-specific 8
Table 2 (continued)
Common GenBank Description
Cluster 5 PP NM_021129 Pyrophosphatase (inorganic)
RAFTLIN D42043 Raft-linking protein
RPL10A NM_007104 Ribosomal protein L10a
SUCLG2 AL050226 Succinate-CoA ligase,
GDP-forming, β subunit
TCERG1 NM_006706 Transcription elongation
regulator 1 (CA150)
VPS45A AF165513 Vacuolar protein
sorting 45A (yeast)
AKR1C3 AB018580 Aldo-keto reductase
family 1, member C3
(3-α hydroxysteroid
dehydrogenase, type II)
CD160 NM_007053 CD160 antigen
CD3Z J04132 CD3Z antigen,
ζ polypeptide
(TiT3 complex)
EAT2 BC022407 SH2 domain-containing
molecule EAT2
Cluster 6 GNLY M85276 Homo sapiens
NKG5 gene, complete cds
GPR56 AL554008 G-protein-coupled
receptor 56
GZMB J03189 Granzyme B
(granzyme 2,
cytotoxic
T-lymphocyte-
associated
serine esterase 1)
GZMH M36118 Granzyme H
(cathepsin G-like 2,
protein h-CCPX)
IFIX AI827431 Interferon-inducible
protein X
KLRC3 NM_002261 Synonyms: NKG2E,
NKG2-E
KLRD1 U30610 Killer cell lectin-like
receptor subfamily D,
member 1
KLRF1 NM_016523 Killer cell lectin-like
receptor subfamily F,
member 1
KLRK1 AF439512 Killer cell lectin-like
receptor subfamily K,
member 1
KSP37 AB021123 Ksp37 protein
MGC61571 BE963026 Hypothetical protein
MGC61571
NKG7 NM_005601 Natural killer cell
group 7 sequence
SAMD3 AI129628 Sterile α motif
domain-containing 3
SPON2 NM_012445 Spondin 2,
extracellular matrix protein
SPUVE NM_007173 Protease, serine, 23
TGFBR3 NM_003243 Transforming
growth factor,
β receptor III
(betaglycan, 300 kDa)
TRD@ X06557 T-cell receptor δ locus
AA227879 Transcribed sequences
Cluster 7 C6orf190 BC043608 Chromosome 6 open
reading frame 207, mRNA
(cDNA clone IMAGE:
5764019), partial cds
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Table 2 (continued)
Common GenBank Description
Cluster 7 CCR7 NM_001838 Chemokine (C-C motif)
receptor 7
CD28 NM_006139 CD28 antigen (Tp44)
GZMK NM_002104 Granzyme K
(serine protease,
granzyme 3; tryptase II)
IL7R NM_002185 Interleukin 7 receptor
LEF1 AF288571 Lymphoid
enhancer-binding
factor 1
MAL NM_002371 Mal, T-cell
differentiation protein
NELL2 NM_006159 NEL-like 2 (chicken)
RGS1 S59049 Regulator of
G-protein signaling 1
TRIM AJ240085 T-cell receptor-interacting
molecule
M12959 Human mRNA for
T-cell receptor α chain
Cluster 8 BCL11B AA918317 B-cell CLL/lymphoma 11B
(zinc finger protein)
CD2 NM_001767 CD2 antigen (p50),
sheep red blood
cell receptor
H963 NM_013308 Platelet-activating
receptor homolog
LCK NM_005356 Lymphocyte-specific
protein tyrosine kinase
LOC283666 AW006185 Hypothetical protein
LOC283666, mRNA
(cDNA clone IMAGE:
4415549), partial cds
TRGV9 M30894 T-cell receptor γ locus
TRGV9 M16768 T-cell receptor
(V-J-C) precursor;
BC040965 Clone IMAGE:5747561,
mRNA
AF043179 H. sapiens T-cell
receptor β chain
(TCRBV13S1–TCRBJ2S1)
mRNA, complete cds
AL559122 T-cell receptor β
chain BV20S1 BJ1-5 BC1
mRNA, complete cds
M15564 T-cell receptor precursor;
human T-cell receptor
rearranged β-chain
V-region (V-D-J) mRNA
Cluster 9 CD8A AW006735 CD8 antigen,
α polypeptide (p32)
A total of 269 genes that are differentially expressed between blood cell types
(parametric one-way ANOVA followed by Student–Newman–Keuls post hoc
test, p < 0.05, with Bonferroni multiple correction) were segregated into nine
clusters using a hierarchical cluster algorithm. Cluster 1, specifically expressed
by monocytes/platelets. Cluster 2, highly expressed by PMNs and, to a lesser
degree, monocytes/platelets. Cluster 3, specifically expressed by PMNs. Cluster
4, highly expressed by B cells and, to a lesser degree, monocytes/platelets.
Cluster 5, expressed by all cell types except PMNs. Cluster 6, highly expressed
by NK cells and, to a lesser degree, CD8+ T cells. Cluster 7, highly expressed by
CD4+ and CD8+ T cells. Cluster 8, highly expressed by CD4+ and CD8+ T cells
and NK cells. Cluster 9, highly expressed by CD8+ T cells and NK cells. Note
that multiple probe sets for the same gene are presented only once.
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expression of genes including NKG5, NKG7, NKG2E, KLRD,
and KLRF1 (cluster 6). Interestingly, genes originally cloned
from cytotoxic T cells such as GZMB and GZMH (granzyme B
and H) have a higher expression in NK cells but are also present
in CD8+ T cells (Figs. 1 and 2; Table 2). The overall genomic
patterns of CD4+ and CD8+ T cells are very similar and can be
distinguished from other cell types by well-known T cell
markers such as CD28 [36], IL7R [37], the chemokine receptor
CCR7 [38], and others (cluster 7). Moreover, a novel gene,
NELL2 [39], that is abundant in neural tissues is also highly
expressed by both CD4+ and CD8+ T cells. Not surprisingly,
CD8 antigen distinguishes CD4+ and CD8+ T cells (cluster 9).
In a recent study of T cells purified from buffy coats from
healthy donors, approximately 50% of the genes in clusters 7
and 8 in this study were present (6/11 and 5/11, respectively)
[14], suggesting that these sets of genes are consistent even with
different purification methodologies and different individuals.
Several limitations of the current study need to be empha-
sized. The purification of most of the cell types was less than
desirable. However, it was for this reason that we identified
gene clusters that are quite different from each other and then
examined how these gene clusters related to the imperfectly
separated cell types in blood (Fig. 1). Using this approach we
can say that the genes or gene clusters that are expressed only
for a given cell type are in fact expressed by that cell type.
Genes that appear to be expressed by two or more cell types
might be shared between those cell types or could be expressed
by only one cell type but could not be differentiated because of
imprecise separation of cells. In addition, a given cell type is
likely to have heterogeneous subtypes, and thus there are likely
to be different gene expression signatures for these subtypes. A
good example is CD4+ cells, among which are Th1 and Th2
CD4+ cells, which have very different functions in the immune
system [40] and which were not differentiated in this study.
Moreover, the increased expression by any given cell type could
be due to a number of different factors including the numbers of
cells. This is not likely to be a major factor since the changes in
gene expression shown usually vary from 5- to 100-fold, and it
is unlikely that the numbers of these types of cells vary this
much.
Other limitations of the results include the negative selection
method of isolating the cells. Even though the selected cells do
not undergo antibody binding used for positive selection, the
negative selection likely activates complement that could affect
the cells being surveyed. In addition, because the negative
selection method does not produce pure populations of cells, it is
possible that the contaminating cells activate the primary cells
being isolated. Therefore, any given profile for each cell type
could represent some degree of activation of the cells. Since the
data at least for the three individuals examined look fairly con-
sistent, if there is nonspecific activation of cells with negative
selection at least it is fairly consistent from one experiment to the
next.
An additional limitation of the current study was the inability
to distinguish gene expression by platelets from gene expression
by monocytes because of the negative selection methods used.
Fig. 2. Cellular origins of genes that have previously been shown to be regulated by ischemic stroke [8], Tourette syndrome [10], and migraine [9]. These genes were
identified from RNA isolated from whole blood by comparing to healthy controls and patients with other diseases. Genes regulated by each disease are listed from top
to bottom (y axis) and their relative expression in each blood cell type is color coded and displayed from left to right (x axis). The list of displayed genes from the top
down for each disorder follows and the genes are numbered and named according to the Affymetrix probe sets: ischemic stroke, 206111_at (RNASE2), 239893_at,
234632_x_at, 206209_s_at (CA4), 203936_s_at (MMP9), 244218_at, 206177_s_at (ARG1), 204351_at (S100P), 232595_at, 228758_at (BCL6), 240440_at (NPL),
225899_x_at (LOC349114), 227129_x_at, 232958_at (PYGL), 205118_at (FPR1), 228642_at, 231029_at, 204714_s_at (F5), 214290_s_at (HIST2H2AA),
218280_x_at (HIST2H2AA), 222303_at, 205863_at (S100A12), 203535_at (S100A9), 206584_at (LY96), 200999_s_at (CKAP4), 207038_at (SLC16A6); Tourette
syndrome, 212775_at (KIAA0657), 207860_at (NCR1), 207796_x_at (KLRD1), 207723_s_at (KLRC3), 206785_s_at (KLRC1), and 210164_at (GZMB); Migraine,
214469_at (HIST1H2AE), 206494_s_at (ITGA2B), 204627_s_at (ITGB3), 216261_at (ITGB3), 209301_at (CA2), 208791_at (CLU), 207156_at (HIST1H2AG),
217216_x_at (MLH3), 204838_s_at (MLH3), 200665_s_at (SPARC), 210299_s_at (FHL1), 206272_at (SPHAR), 201818_at (FLJ12443), 211506_s_at (IL8),
209864_at (FRAT2), 202859_x_at (IL8), 201473_at (JUNB), 217143_s_at (TRD@), 210031_at (CD3Z), 205898_at (CX3CR1), 201272_at (AKR1B1), 202567_at
(SNRPD3) 204655_at (CCL5).
700 X. Du et al. / Genomics 87 (2006) 693–703However, gene expression profiles for platelets have been
published [18,20]. It is notable that platelets lack a nucleus and
nuclear DNA, and hence the mRNA found in platelets is derived
from the megakaryocytes that form the platelets. A similar
situation exists for red blood cells, which contain mRNA but
have no nucleus or nuclear DNA. The importance of
differentiating platelet from monocyte RNAs is emphasized
by the data in Fig. 2. Even though stroke and migraine appear to
express genes in both platelets and monocytes, careful
examination of the gene lists for both shows that in stroke the
genes induced are mainly in monocytes, and in migraine the
genes are induced mainly in platelets (see below). It is certainly
possible that a genetic disease like migraine could be associated
with changes in gene expression in platelets and not other
cellular elements in the blood. This is emphasized by a number
of clinical studies in migraine as mentioned next.Finally, it is important to reemphasize that the data shown
in this study are for expression in three normal, healthy
individuals, and the data for the three diseases were obtained
by comparing the published disease-regulated genes to the
genes expressed by different cell types in the healthy persons
in this study. The expression profiles for the individual cell
types shown here can be viewed only as being preliminary,
since only three individuals were studied. Large numbers of
individuals may be necessary to derive reliable gene profiles
for individual cell types in blood, since age, gender, race,
genetic background, lifestyle, diet, concurrent diseases and
medications, and many other factors are likely to influence
cell type-related gene expression. The current study does,
however, emphasize the need for future studies to isolate
these cell types in individuals with each disease and replicate
the gene expression profiles for each cell type in each
701X. Du et al. / Genomics 87 (2006) 693–703individual with each disease. An unexpected benefit to isolating
individual cell types was that the fold differences of gene
expression is 10- to 100-fold, compared to fold changes in whole
blood, at least in neurological diseases, on the order of 2- to 3-
fold [6–10,13–17,41]. The ability to detect high fold changes in
these cell-specific data could be due in part to removal of high-
abundance RNAs that populate whole blood and in part to using
an approach that highlights cell differences rather than averaging
them.
The data shown suggest that the cell type-specific data
could serve as a powerful guide to understanding the relative
contribution of each cell type to the overall gene expression
profile caused by various diseases. The data show that
different neurological diseases affect gene expression through
distinct blood cell populations. Tourette syndrome, a
neuropsychiatric tic disorder that has been proposed to be
caused by an autoimmune response to streptococcus at least
in some patients [42,43], appears to be associated with
changes in gene expression in NK cells and/or CD8+ cells
based upon the results of this study and our previous findings
[10]. In contrast, the blood genomic response following acute
ischemic stroke was predominantly from PMNs based upon
the current findings and those of our recent ischemic stroke
study [8]. This agrees with human and animal studies
showing that polymorphonuclear cells are the major cell
type that initially infiltrate areas of cerebral infarction
following stroke and appear to play a major role in
pathogenesis [44–46]. Importantly, infection and predisposi-
tion to inflammation may be risk factors for stroke [47]. In
comparison, the blood genomic pattern for migraine headache
is more heterogeneous, with several blood cell types affected,
including platelets and monocytes. Platelets and abnormalities
of serotonin in platelets have long been implicated in the
pathogenesis of migraine and its genetic basis and may
contribute to an increased risk of stroke [48–51]. These data
suggest that although neuroinflammation plays a crucial role
in the pathological process of both cerebral ischemia [52] and
migraine [53], the involved blood cells and genes are distinct.
This further underscores the importance of identifying the
blood cell types associated with a given disorder, to formulate
mechanistic hypotheses and accurately characterize surrogate
blood markers for diagnostic, prognostic, and treatment
purposes.
Materials and methods
Separation of blood cell subtypes
Blood was drawn from three healthy donors for all cell subsets. The
donors were healthy, ages 32, 33, and 59; two were male; and none had any
concurrent infection or major medical illnesses. Subsets of mononuclear cells
including CD4+ T cells, CD8+ T cells, CD19+ B cells, CD56+ NK cells, and
CD14+ monocytes were enriched using the RosetteSep negative selection
method (StemCell Technologies, BC, Canada). This method was chosen as it
provided a short processing time and the desired cell types remain largely
undisturbed. This method thus helped to minimize potential alterations in
gene expression due to excessive handling during the cell isolation and to
avoid possible effects of positive selection of cells on gene expression
[21,22]. For each cell subtype, 8 ml whole blood was drawn into VacutainerCPT cell preparation tubes that contained sodium citrate and Ficoll (Becton–
Dickinson, NJ, USA). Four hundred microliters of RosetteSep antibody
cocktail was added to each tube and incubated for 20 min at room
temperature. The antibody cocktail cross-links unwanted cells in whole blood
to red blood cells, forming immunorosettes with increased density. After
incubation, the blood collected in the CPT tubes was centrifuged for 20 min
at 1800 g to precipitate the unwanted cells and precipitate free RBCs. The
desired cells, not labeled with antibody, were collected from the plasma:Ficoll
interface and washed once with PBS and the RNA was isolated using Trizol
reagent. The purity of cells separated with this protocol was 90 ± 5% for
CD4+ T cells, 76 ± 8% for CD8+ T cells, 81 ± 8% for CD19+ B cells,
74 ± 10% for CD56+ NK cells, and 69 ± 12% for CD14+ monocytes
(mean ± SD) according to confirmatory flow cytometry data provided by the
manufacturer.
It is noted that platelet contamination has been reported for CD14+
monocytes using the RosetteSep enrichment method. Therefore, the “monocyte”
gene expression pattern obtained in this study may come from both monocytes
and platelets and is therefore referred to as “mono/platelet” in the text. However,
importantly, platelet contamination is not seen in lymphocyte enrichments as the
lymphocyte enrichment cocktails contain anti-CD36, which removes platelets
along with monocytes.
For the separation of PMNs, 6 ml sodium citrate–anti-coagulated venous
blood was carefully layered on 3 ml leukocyte separation media (Histopaque-
1119 and Histopaque-1077; Sigma–Aldrich, St. Louis, MO, USA). After a 700g
centrifugation for 30 min at room temperature, the “mononuclear” layer together
with fluid within 0.5 cm of this layer was aspirated and discarded, while the
“granulocyte” layer was transferred to a new tube and washed once with
phosphate-buffered saline. The purity of the PMNs obtained was ∼98% based
on microscopic examination after Wright–Giemsa staining.
RNA isolation
The collected pellets of each cell subtype were immediately homogenized
with Trizol reagent (Invitrogen, Carlsbad, CA, USA). The aqueous phase
containing RNAwas separated by centrifugation after adding chloroform. RNA
was recovered by precipitation with isopropyl alcohol and washed with 75%
ethanol. RNA samples were quantified using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA) and the
quality was assessed using an Agilent 2100 bioanalyzer (Agilent, Palo Alto, CA,
USA). We processed RNA only when the A260/A280 absorbance ratio of the
cleaned RNA exceeded 2.0 and 28S/18S ratio equaled or exceeded 1.8 for these
microarray studies.
Microarray processing
For each blood cell subtype (CD4+ T cells, CD8+ T cells, CD19+ B cells,
CD56+ NK cells, CD14+ monocytes, and PMNs), 25 ng total RNA was
labeled using a two-cycle target labeling protocol and hybridized to arrays. A
total of 36 (6 arrays for each cell type, for three subjects, with technical
duplicates done for each) Affymetrix Human 2.0 Plus arrays were used
(Affymetrix, Santa Clara, CA, USA) in this study, with each array containing
54,675 probe sets referred to as such or as “genes” in the text. Six arrays for
each cell type were used for each of the three subjects (n = 18 arrays), and
technical duplicates of these were then processed (n = 36 arrays total). The
probe sets were on one chip that surveyed 47,000 transcripts from ∼39,500
potential human genes (Affymetrix Technical Manual). Sample labeling,
hybridization to chips, and image scanning were performed according to the
Affymetrix Expression Analysis Technical Manual.
Data analysis
After the arrays were scanned, the raw expression values (probe level
data) for each gene were saved in Affymetrix.cel and Affymetrix.dat files.
The probe level data were then collated using GC-Robust Multi-array
Average (GCRMA-EB) software (http://www.bioconductor.org/). This in-
volved nonlinear background reduction, quantile normalization, and summa-
rization by median polishing [23,24]. The technical replicates were averaged,
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individuals and six different cell types for each individual). We used both
qualitative and quantitative methods to assess the expression signatures of
each cell type.
Qualitative method
This method was used to determine genes that are uniquely expressed by
each cell type. Affymetrix GCOS software was used to generate “detection
calls,” i.e., “present,” “absent,” or “marginal,” for each gene on each array
based on Wilcoxon's signed rank test (http://www.affymetrix.com/support/
technical/technotes/statistical_reference_guide.pdf). Briefly, the present genes
represent transcripts that can be clearly detected by arrays, while the absent
calls are generally given to transcripts that are below the detection threshold
and cannot be reliably distinguished from noise. We determined the number
of genes that are present in each cell type (with 3 present calls in three arrays
regardless of calls from other cell types) and the number of genes that are
present only in each specific cell type (with 3 present calls in three arrays and
15 absent calls in all other cell types). This method tends to eliminate genes
that are marginally associated with a given cell type. As noted above, the
technical replicates were averaged together for this qualitative analysis and
the quantitative analysis that follows.
Quantitative methods
The probe level data from .cel files were first collated using Robust Multi-
array Average (RMA) software (http://www.bioconductor.org/). After nonlinear
background reduction and quantile normalization and summarization, probe
level data were generated by median polishing each gene to produce a
quantitative expression assessment in each cell sample [23,24]. Genes that were
differentially expressed among cell subtypes were identified using a parametric
one-way ANOVA followed by the Student–Newman–Keuls post hoc test with
subtype as the variable (GENESPRING 7 software; Silicon Genetics, Redwood
City, CA, USA). The type I error probability value (p value) was corrected with
the Bonferroni method for multiple test comparisons and p < 0.05 was
considered significant. The identified genes were subjected to a hierarchical
cluster analysis using Pearson correlation as the similarity measure (Fig. 1).
Cellular origin of genes regulated by ischemic stroke, migraine, and
Tourette syndrome
The genes up-regulated by ischemic stroke, migraine, and Tourette
syndrome were identified in three previous studies by comparing these
conditions to healthy controls and patients with other neurological disorders.
RNA isolated from whole blood was used for all of these previous studies. The
ischemic stroke study was performed using U133 2.0 Plus arrays [8], while the
Tourette and migraine studies were carried out using human U95Av 2 arrays
[9,10]. For the ischemic stroke study 45 stroke samples were compared to 14
healthy control samples [8]. For the migraine headache study 22 patients with
migraine were compared to 56 control samples from patients with a variety of
other disorders [9]. For the Tourette syndrome study, 16 patients with Tourette
syndrome who had at least one first degree relative with Tourette syndrome were
compared to 113 samples from control patients with a variety of other disorders
including epilepsy and headache and healthy controls [10]. With the current
subtype-specific expression data, we attempted to address the cell types that are
affected by each disease. To make a direct comparison, genes from Affymetrix
U95Av 2 arrays were matched to genes on the Affymetrix U133 2.0 Plus arrays
through the Netaffx database (www.affymetrix.com) and their expression across
different blood cell types was examined and visualized (Fig. 2).Acknowledgments
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